BACKGROUND: Prostate carcinoma is a major cause of morbidity and mortality. The MAPK Signaling Pathway plays an important role in multiple tumors, including prostate carcinoma. MAPK signaling is mediated by ERK1/2, JNK and p38 MAPK, which are important in the control of cell proliferation, differentiation and apoptosis. However, relatively little is known about the regulatory mechanism of p38 MAPK in prostate cancers. NOB1 is among the most novel topic in MAPK studies currently. Recent studies found its vital role in tumor metastasis in glioblastoma proliferation, however, its expression profile and its prognostic value in prostate carcinoma have not been investigated. METHODS: To determine the relationship between NOB1 and p38 MAPK expressions, a population-based study was conducted for immunohistochemical staining analysis of tumor tissues, in matched malignant and nonmalignant prostatectomy samples from 132 PCa patients. Moreover, Western blot analysis and NOB1 interference studies of prostate cancer cell lines. To evaluate the diagnostic and prognostic between NOB1 and p38 MAPK in prostate cancer (PCa) tissue after radical prostatectomy, the hypothesis that prostate cancers with NOB1 expression have distinct clinical, prognostic and molecular attributes was tested. RESULTS: Among 132 prostate cancers, NOB1 expression was detected in 117 (88.7%) tumors by immunohistochemistry. NOB1 and p38 MAPK expression had significant positive correlation with carcinogenesis, tumor progression and patient survival. Immunohistochemically, NOB1 expression in prostate cancer was independently associated with p38 MAPK activation (P=0.0002). Furthermore, p38 MAPK expression was completely suppressed by NOB1 interference in the prostate cancer cell lines DU-145 and PC-3. CONCLUSIONS: NOB1 expression status was closely correlated with important histopathologic characteristics and the recurrence and metastasis of prostate carcinomas. These data support a potential link between NOB1 and p38 MAPK, and suggest that NOB1 may identify a subset of prostate cancer patients with a poor prognosis. This study proved that NOB1 in PCa tissue can be used, in combination with traditional clinicopathological factors, as promising diagnostic and prognostic tools.
BACKGROUND:Prostate carcinoma is a major cause of morbidity and mortality. The MAPK Signaling Pathway plays an important role in multiple tumors, including prostate carcinoma. MAPK signaling is mediated by ERK1/2, JNK and p38MAPK, which are important in the control of cell proliferation, differentiation and apoptosis. However, relatively little is known about the regulatory mechanism of p38MAPK in prostate cancers. NOB1 is among the most novel topic in MAPK studies currently. Recent studies found its vital role in tumor metastasis in glioblastoma proliferation, however, its expression profile and its prognostic value in prostate carcinoma have not been investigated. METHODS: To determine the relationship between NOB1 and p38MAPK expressions, a population-based study was conducted for immunohistochemical staining analysis of tumor tissues, in matched malignant and nonmalignant prostatectomy samples from 132 PCa patients. Moreover, Western blot analysis and NOB1 interference studies of prostate cancer cell lines. To evaluate the diagnostic and prognostic between NOB1 and p38MAPK in prostate cancer (PCa) tissue after radical prostatectomy, the hypothesis that prostate cancers with NOB1 expression have distinct clinical, prognostic and molecular attributes was tested. RESULTS: Among 132 prostate cancers, NOB1 expression was detected in 117 (88.7%) tumors by immunohistochemistry. NOB1 and p38MAPK expression had significant positive correlation with carcinogenesis, tumor progression and patient survival. Immunohistochemically, NOB1 expression in prostate cancer was independently associated with p38MAPK activation (P=0.0002). Furthermore, p38MAPK expression was completely suppressed by NOB1 interference in the prostate cancer cell lines DU-145 and PC-3. CONCLUSIONS:NOB1 expression status was closely correlated with important histopathologic characteristics and the recurrence and metastasis of prostate carcinomas. These data support a potential link between NOB1 and p38MAPK, and suggest that NOB1 may identify a subset of prostate cancerpatients with a poor prognosis. This study proved that NOB1 in PCa tissue can be used, in combination with traditional clinicopathological factors, as promising diagnostic and prognostic tools.
Authors: Dagmar Faust; Christina Schmitt; Franz Oesch; Barbara Oesch-Bartlomowicz; Ilona Schreck; Carsten Weiss; Cornelia Dietrich Journal: Cell Commun Signal Date: 2012-03-09 Impact factor: 5.712
Authors: Thomas Veith; Roman Martin; Jan P Wurm; Benjamin L Weis; Elke Duchardt-Ferner; Charlotta Safferthal; Raoul Hennig; Oliver Mirus; Markus T Bohnsack; Jens Wöhnert; Enrico Schleiff Journal: Nucleic Acids Res Date: 2011-12-10 Impact factor: 16.971
Authors: Marjaana Ojalill; Marjaana Parikainen; Pekka Rappu; Elina Aalto; Johanna Jokinen; Noora Virtanen; Elina Siljamäki; Jyrki Heino Journal: Oncotarget Date: 2018-08-21
Authors: Yu Zhao; Yizhou Zheng; Jie Wang; Shuyi Ma; Yiming Yu; William Lindsey White; Shiping Yang; Fan Yang; Jun Lu Journal: Mar Drugs Date: 2018-09-09 Impact factor: 5.118